Pfizer (PFE) Change in Cash (2009 - 2026)
Pfizer (PFE) posted quarterly Change in Cash of $563.0 million for Q1 2026, up 50.13% year-over-year from $375.0 million in Q1 2025, and up 387.24% quarter-over-quarter from -$196.0 million in Q4 2025.
Pfizer (PFE) Change in Cash (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Change in Cash for 18 consecutive years, with $563.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Cash rose 50.13% year-over-year to $563.0 million; the TTM figure through Mar 2026 stood at $279.0 million (up 108.76% YoY), while the FY2025 annual figure was $91.0 million, up 105.03% from the prior year.
- Change in Cash improved to $563.0 million in Q1 2026 per PFE's latest filing, from -$196.0 million in the prior quarter.
- Across five years, Change in Cash topped out at $1.8 billion in Q2 2023 and bottomed at -$2.1 billion in Q1 2024.
- Historically, Change in Cash has averaged -$88.5 million across 5 years, with a median of $213.0 million in 2025.
- Annual changes were most pronounced in 2022 — Change in Cash surged 3626.67% — and 2024, when it plunged 221.84%.
- Pfizer's Change in Cash stood at -$688.0 million in 2022, then jumped by 54.07% to -$316.0 million in 2023, then slumped by 458.54% to -$1.8 billion in 2024, then jumped by 88.9% to -$196.0 million in 2025, then jumped by 387.24% to $563.0 million in 2026.
- Business Quant data shows PFE's Change in Cash at $563.0 million in Q1 2026, -$196.0 million in Q4 2025, and -$301.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -1.27 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -2.82 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1.49 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 739.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1.95 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -4.45 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -727.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -14.32 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | -727.00 Mn |
| Mar 29, 2026 | 563.00 Mn |
| Dec 31, 2025 | -196.00 Mn |
| Sep 28, 2025 | -301.00 Mn |
| Jun 29, 2025 | 213.00 Mn |
| Mar 30, 2025 | 375.00 Mn |
| Sep 29, 2024 | -1.77 Bn |
| Jun 30, 2024 | 343.00 Mn |
| Mar 31, 2024 | -2.14 Bn |
| Dec 31, 2023 | -316.00 Mn |
| Jul 2, 2023 | 475.00 Mn |
| Apr 2, 2023 | 1.75 Bn |
| Jul 3, 2022 | -688.00 Mn |
| Apr 3, 2022 | 529.00 Mn |
| Oct 3, 2021 | 209.00 Mn |
| Jul 4, 2021 | 608.00 Mn |
| Apr 4, 2021 | -15.00 Mn |
| Sep 27, 2020 | 277.00 Mn |
| Jun 28, 2020 | -351.00 Mn |
| Mar 29, 2020 | 846.00 Mn |